Olympus Corp
TSE:7733
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2 021.5
2 850
|
Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one Olympus Corp stock under the Base Case scenario is 2 738.12 JPY. Compared to the current market price of 2 666.5 JPY, Olympus Corp is Undervalued by 3%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Olympus Corp
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for Olympus Corp cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Olympus Corp., a global leader in optical and digital precision technology, has carved a remarkable niche in the healthcare and life sciences sectors. Founded in Japan in 1919, the company initially focused on cameras and microscopes but has since evolved into a dominant player in the medical device arena, particularly known for its innovative imaging systems, endoscopy equipment, and surgical solutions. Olympus's commitment to enhancing healthcare outcomes is underscored by its significant investments in research and development, enabling the company to deliver cutting-edge solutions that improve patient care and empower healthcare professionals. With a strong presence in over 40 countries,...
Olympus Corp., a global leader in optical and digital precision technology, has carved a remarkable niche in the healthcare and life sciences sectors. Founded in Japan in 1919, the company initially focused on cameras and microscopes but has since evolved into a dominant player in the medical device arena, particularly known for its innovative imaging systems, endoscopy equipment, and surgical solutions. Olympus's commitment to enhancing healthcare outcomes is underscored by its significant investments in research and development, enabling the company to deliver cutting-edge solutions that improve patient care and empower healthcare professionals. With a strong presence in over 40 countries, Olympus not only addresses prevailing healthcare challenges but also actively participates in the global push toward minimally invasive procedures, thereby appealing to a growing segment of health-conscious patients and cost-sensitive healthcare systems.
For investors, Olympus Corp. presents an intriguing opportunity characterized by resilient financial performance and strategic growth initiatives. The company has consistently demonstrated robust revenue generation, bolstered by its leadership in the endoscopy market, which accounts for a substantial portion of its sales. Furthermore, Olympus is strategically focused on expanding its product offerings through acquisitions and collaborations, reinforcing its commitment to innovation. The growing demand for minimally invasive surgeries, driven by advances in technology and patient preferences, positions Olympus favorably for future growth. With its solid foundation, continuous evolution, and commitment to sustainability, Olympus Corp. stands as a compelling investment option for those looking to align with a company dedicated to transforming healthcare and enhancing lives.
Olympus Corporation operates in several core business segments, primarily focused on imaging and medical technologies. Here are the main segments:
-
Medical Systems: This is one of Olympus's largest segments, which includes endoscopic equipment and systems used in minimally invasive surgeries. The segment focuses on products for gastrointestinal, respiratory, and surgical applications, as well as diagnostic imaging and therapeutic devices.
-
Scientific Solutions: This segment comprises products and services for scientific research and industrial applications. It includes microscopy systems, digital imaging systems, and various analytical instruments used in life sciences, materials testing, and industrial applications.
-
Consumer & Professional Imaging: Although historically significant, the consumer imaging segment has diminished in prominence. This segment includes digital cameras, voice recorders, and other imaging products, catering to both consumer and professional markets.
-
Industrial Solutions: This segment focuses on precision measurement and testing equipment used in industrial applications. It includes tools for non-destructive testing and measurement in various industries, helping to ensure product quality and safety.
Each of these segments reflects Olympus’s commitment to innovation and technology in enhancing healthcare and industrial processes, positioning the company as a leader in these respective fields.
Olympus Corporation, a prominent player in the imaging and medical sectors, leverages several unique competitive advantages that set it apart from its rivals:
-
Market Leadership in Medical Imaging: Olympus is highly regarded for its endoscopic equipment and imaging systems. Its reputation for high-quality products and innovations, particularly in minimally invasive surgeries, positions it as a leader in the medical field.
-
Strong R&D Investment: Olympus invests significantly in research and development, allowing it to innovate continuously. This commitment enables the company to stay ahead in terms of technology and product offerings, particularly in the medical and scientific markets.
-
Brand Reputation and Trust: With decades of experience, Olympus has built a strong brand associated with quality and reliability. Healthcare professionals often prefer Olympus products due to the trust established through years of consistent performance.
-
Diverse Product Portfolio: Olympus offers a broad range of products, including endoscopy, surgical systems, and imaging technologies, as well as consumer products. This diversity enables the company to cater to various market needs and customer segments.
-
Innovation in Endoscopy: Olympus has pioneered advanced endoscopic techniques and technologies, such as the development of 4K and 3D imaging systems, which enhance the quality of medical procedures and outcomes.
-
Global Reach and Distribution Network: Olympus has a well-established global presence, providing access to diverse markets. Its efficient distribution and service network ensure timely delivery and support, enhancing customer satisfaction.
-
Focus on Training and Education: Olympus places a strong emphasis on training healthcare professionals regarding the use of its equipment, leading to better clinical outcomes and reinforcing customer loyalty.
-
Commitment to Sustainability: The company is increasingly emphasizing sustainable practices in its operations, resonating well with environmentally conscious consumers and healthcare institutions.
-
Strategic Partnerships and Collaborations: Olympus has established collaborations with various stakeholders in the healthcare ecosystem, enhancing its innovation capabilities and market reach.
These competitive advantages contribute to Olympus Corporation's robust position within the medical technology and imaging sectors, enabling it to differentiate itself from competitors effectively.
Olympus Corporation, a multinational corporation known for its imaging and medical equipment, faces several risks and challenges that could impact its operations and profitability in the near future:
-
Market Competition: The medical technology and imaging markets are highly competitive, with both established companies and new entrants. Innovations by competitors could lead to a loss of market share for Olympus.
-
Regulatory Changes: As a manufacturer of medical devices, Olympus is subject to stringent regulations by authorities like the FDA and EMA. Changes in regulatory requirements can delay product approvals and increase compliance costs.
-
Technological Advancements: Rapid advancements in technology necessitate continuous investment in R&D. Failing to innovate or keep pace with technological changes could make Olympus’s products obsolete.
-
Economic Uncertainty: Global economic instability can affect healthcare budgets and spending. In times of economic downturn, hospitals and clinics may postpone or reduce purchases of expensive medical equipment.
-
Supply Chain Disruptions: The COVID-19 pandemic highlighted vulnerabilities in global supply chains. Future disruptions, whether due to health crises, geopolitical tensions, or natural disasters, could affect Olympus's production capabilities.
-
Currency Fluctuations: As a global company, Olympus is exposed to currency exchange risks. Fluctuations in exchange rates could affect profitability on international sales.
-
Cybersecurity Threats: With increasing digitization and reliance on connected devices, cybersecurity threats present a significant risk. A cyber-attack could lead to disruptions, data breaches, and loss of consumer trust.
-
Intellectual Property Risks: Protecting proprietary technology is crucial. Violations of patents or the introduction of counterfeit products can adversely affect market performance.
-
Changing Consumer Preferences: In the medical field, there is an ongoing shift towards minimally invasive procedures and smart devices. Olympus must adapt its product line to meet these evolving preferences.
-
Environmental Regulations and Sustainability: Growing emphasis on sustainability and environmental regulations can lead to increased operational costs and necessitate changes in production practices.
-
Aging Population: While an aging global population presents opportunities in the healthcare sector, it also increases competition as more firms target this demographic with specialized products and services.
-
Mergers and Acquisitions: The landscape of the medical technology industry is continuously evolving with mergers and acquisitions. Their impact can change the competitive dynamics in unforeseen ways.
By addressing these challenges proactively, Olympus can better position itself for future growth and stability.
Revenue & Expenses Breakdown
Olympus Corp
Balance Sheet Decomposition
Olympus Corp
Current Assets | 736.6B |
Cash & Short-Term Investments | 284.4B |
Receivables | 214.9B |
Other Current Assets | 237.3B |
Non-Current Assets | 778.8B |
Long-Term Investments | 47B |
PP&E | 272.9B |
Intangibles | 286.7B |
Other Non-Current Assets | 172.1B |
Current Liabilities | 419.2B |
Accounts Payable | 57.9B |
Other Current Liabilities | 361.3B |
Non-Current Liabilities | 306.1B |
Long-Term Debt | 184.6B |
Other Non-Current Liabilities | 121.5B |
Earnings Waterfall
Olympus Corp
Revenue
|
963.3B
JPY
|
Cost of Revenue
|
-319.2B
JPY
|
Gross Profit
|
644.1B
JPY
|
Operating Expenses
|
-595.2B
JPY
|
Operating Income
|
48.9B
JPY
|
Other Expenses
|
-32.3B
JPY
|
Net Income
|
16.6B
JPY
|
Free Cash Flow Analysis
Olympus Corp
JPY | |
Free Cash Flow | JPY |
In the first quarter of fiscal year 2025, the company saw a consolidated revenue increase by 15% year-on-year, bolstered by strong sales in North America and a favorable yen depreciation. The EVIS X1 GI endoscopy system and other core areas like Urology and Respiratory showed robust growth. Despite challenges in China due to the anticorruption campaign, the company maintained its guidance for fiscal year 2025. Operating profit grew by 21%, and adjusted operating profit surged by 32%. Investments in strategic growth and quality transformation programs continue. The company's focus remains on consolidating its market position while expecting a cautious recovery in China.
What is Earnings Call?
Profitability Score
Profitability Due Diligence
Olympus Corp's profitability score is 56/100. The higher the profitability score, the more profitable the company is.
Score
Olympus Corp's profitability score is 56/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Olympus Corp's solvency score is 66/100. The higher the solvency score, the more solvent the company is.
Score
Olympus Corp's solvency score is 66/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Olympus Corp
According to Wall Street analysts, the average 1-year price target for Olympus Corp is 3 114.71 JPY with a low forecast of 2 424 JPY and a high forecast of 3 675 JPY.
Dividends
Current shareholder yield for Olympus Corp is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Olympus Corp. engages in the manufacture and sale of precision machineries and instruments. The company is headquartered in Shinjuku, Tokyo-To and currently employs 31,653 full-time employees. The firm operates in five business segments. The Endoscopy segment provides gastrointestinal endoscopy, surgical endoscopy, endoscopy systems and repair services. The Therapeutic Equipment segment provides endoscopic treatment tools, energy devices, urology, gynecology and otolaryngology products. The Scientific segment provides biological microscope, industrial microscope, industrial endoscope and non-destructive inspection equipment. The Imaging segment provides digital cameras and recording machines. The Others segment is engaged in the manufacture and sale of biomaterials. The firm is also engaged in the financial investment business.
Contact
IPO
Employees
Officers
The intrinsic value of one Olympus Corp stock under the Base Case scenario is 2 738.12 JPY.
Compared to the current market price of 2 666.5 JPY, Olympus Corp is Undervalued by 3%.